These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 2896458)
1. Sulfasalazine: I. An historical perspective. Bachrach WH Am J Gastroenterol; 1988 May; 83(5):487-96. PubMed ID: 2896458 [No Abstract] [Full Text] [Related]
2. Clinical trials in ulcerative colitis: II. Historical review. Margolin ML; Krumholz MP; Fochios SE; Korelitz BI Am J Gastroenterol; 1988 Mar; 83(3):227-43. PubMed ID: 2894170 [No Abstract] [Full Text] [Related]
3. [Aminosalicylates in chronic inflammatory intestinal diseases and rheumatoid arthritis]. Maier KP Dtsch Med Wochenschr; 1992 Oct; 117(42):1614-5. PubMed ID: 1356747 [No Abstract] [Full Text] [Related]
4. The use of sulfasalazine in the treatment of inflammatory bowel disease. Spector R J Iowa Med Soc; 1983 Jun; 73(6):230-4. PubMed ID: 6135735 [No Abstract] [Full Text] [Related]
5. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Svartz N Am J Gastroenterol; 1988 May; 83(5):497-503. PubMed ID: 2896459 [TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive therapy of inflammatory bowel disease: a historical perspective. Korelitz BI Gastroenterologist; 1995 Jun; 3(2):141-52. PubMed ID: 7640945 [TBL] [Abstract][Full Text] [Related]
7. [40 years of salazosulfapyridine. Is end in sight?]. van Hees PA; van Tongeren JH Ned Tijdschr Geneeskd; 1982 Oct; 126(44):2014-8. PubMed ID: 6129576 [No Abstract] [Full Text] [Related]
8. [Exacerbation of ulcerative colitis and Crohn disease as a phenomenon inherent in the disease]. Habs M; Schifmann R Dtsch Med Wochenschr; 1986 Jul; 111(28-29):1131. PubMed ID: 2874004 [No Abstract] [Full Text] [Related]
9. Pancreatitis and pancreatic necrosis during sulfasalazine therapy. Faintuch J; Mott CB; Machado MC Int Surg; 1985; 70(3):271-2. PubMed ID: 2872181 [TBL] [Abstract][Full Text] [Related]
11. [Salozosulphapyridine and its metabolites in ulcerative colitis and Crohn disease]. Rubinstein BE Ugeskr Laeger; 1982 Feb; 144(5):304-6. PubMed ID: 6122297 [No Abstract] [Full Text] [Related]
12. [Azulfidine/Salazopyrin therapy during pregnancy]. Fahrländer H Z Gastroenterol Verh; 1981 Jun; 19():24-6. PubMed ID: 6168128 [No Abstract] [Full Text] [Related]
13. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease. Korelitz BI; Present DH; Rubin PH; Fochios SE J Clin Gastroenterol; 1984 Feb; 6(1):27-31. PubMed ID: 6142067 [TBL] [Abstract][Full Text] [Related]
14. [Side effects of salicylazosulfapyridine therapy]. Miller B Dtsch Med Wochenschr; 1980 Nov; 105(46):1596-7. PubMed ID: 6108200 [No Abstract] [Full Text] [Related]
15. [Pulmonary diffusing capacity disorder in nonspecific intestinal inflammations unexplainable by acetylation phenotype or treatment with sulfasalazine]. Bures J; Horácek J; Tilser P; Fixa B; Komárková O; Tichý M; Zaydlar K; Král B Cas Lek Cesk; 1986 Jul; 125(29):905-9. PubMed ID: 2873894 [No Abstract] [Full Text] [Related]
16. The drug therapy of ulcerative colitis and of Crohn's disease. Tumen HJ Semin Drug Treat; 1974; 3(4):339-49. PubMed ID: 4150770 [No Abstract] [Full Text] [Related]
18. Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease. Laasila K; Leirisalo-Repo M Scand J Rheumatol; 1994; 23(6):338-40. PubMed ID: 7801059 [TBL] [Abstract][Full Text] [Related]